Glp-1 Receptor Agonist And Smoking Cessation Support

The Hidden Details of Glp-1 Receptor Agonist And Smoking Cessation Support Revealed

The use of GLP

Key Details About Glp-1 Receptor Agonist And Smoking Cessation Support

This systematic review evaluates the efficacy, tolerability, and neurobiological rationale of glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) and dual GLP -1/glucose-dependent insulinotropic peptide (GIP) agonists in treating nicotine use disorder (NUD), with particular attention to smoking abstinence, craving reduction, weight gain ...

Illustration of Glp-1 Receptor Agonist And Smoking Cessation Support
Glp-1 Receptor Agonist And Smoking Cessation Support

New research presented today at the American Psychiatric Association's Annual Meeting shows that GLP-1 receptor agonists may be able to help cigarette smokers reduce weight gain while they are quitting.

Therapeutic Potential of GLP

Illustration of Glp-1 Receptor Agonist And Smoking Cessation Support
Glp-1 Receptor Agonist And Smoking Cessation Support

Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonist And Smoking Cessation Support.

Preclinical findings show that GLP-1 receptor agonists ( GLP -1RA) modulate nicotine reward, reduce nicotine self- administration, and prevent withdrawal-related hyperphagia. Early clinical investigations suggest that GLP -1RA prevent post- cessation weight gain, while potentially improving cessation or reducing craving.

Visual Collection